Mahidol Vivax Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
Biologics Research & Development, Walter Reed Army Institute of Research, Silver Spring, MD, United States.
Front Immunol. 2023 Jan 5;13:1006954. doi: 10.3389/fimmu.2022.1006954. eCollection 2022.
Controlled Human Malaria Infection models (CHMI) have been critical to advancing new vaccines for malaria. Stringent and safe preparation of a challenge agent is key to the success of any CHMI. Difficulty producing the parasite has limited production of qualified parasites for CHMI as well as the functional assays required to screen and down-select candidate vaccines for this globally distributed parasite. This and other challenges to CHMI (CHMI), including scientific, logistical, and ethical obstacles, are common to research conducted in both non-endemic and endemic countries, with additional hurdles unique to each. The challenges of using CHMI for vaccine development and evaluation, lessons learned from previous and ongoing clinical trials, and the way forward to effectively perform CHMI to support vaccine development, are discussed.
人体疟疾感染控制模型（CHMI）对于推进疟疾新疫苗的发展至关重要。严格、安全地制备挑战剂是任何 CHMI 成功的关键。寄生虫难以产生，这限制了合格寄生虫的生产，也限制了功能检测的开展，而这些对于筛选和逐步淘汰候选疫苗都是必需的，因为这种寄生虫在全球范围内分布。CHMI（人体疟疾感染控制模型）面临的这些挑战以及其他挑战，包括科学、后勤和伦理方面的障碍，在非流行和流行国家开展的研究中都很常见，每个国家还有各自独特的障碍。本文讨论了使用 CHMI 进行疫苗开发和评估的挑战、从以往和正在进行的临床试验中吸取的经验教训，以及有效开展 CHMI 以支持疫苗开发的前进道路。
